• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Subconjunctival conbercept for the treatment of corneal neovascularization

    2023-06-17 06:52:18CunSunFangRuanShangLiJianQiangZhangYingJie

    Cun Sun, Fang Ruan, Shang Li, Jian-Qiang Zhang, Ying Jie

    1Department of Ophthalmology, Beijing Huimin Hospital,Beijing 100053, China

    2Department of Ophthalmology, Beijing You’an Hospital,Capital Medical University, Beijing 100054, China

    3Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University,Beijing Ophthalmology and Visual Sciences Key Lab, Beijing 100730, China

    Abstract● AIM: To investigate the effectiveness and safety of subconjunctival injection of conbercept in the treatment of corneal neovascularization (CNV).

    ● KEYWORDS: corneal neovascularization; conbercept;anti-vascular endothelial growth factor; subconjunctival injection

    INTRODUCTION

    Corneal neovascularization (CNV) is the in-growth of new immature vasculature from the limbus into the avascular corneal tissue, which could lead to the opacification of the transparent cornea.As a highly prevalent cause of blindness in the world, CNV affects over 1.4 million people annually,12% of whom suffer subsequent vision loss[1-2].To date,the treatment of CNV includes local use of glucocorticoids and non-steroid anti-inflammatory medications, laser photocoagulation, fine needle diathermy, photodynamic therapy, and conjunctival, limbal, and amniotic membrane transplantation, all with however suboptimal effectiveness[1,3].One potential explanation for the suboptimal effectiveness might be that none of these treatments targets the molecular mediators of angiogenesis.

    Recently, inhibitors of vascular endothelial growth factor(VEGF), which is the most important regulatory factor for angiogenesis, have shown good clinical application prospects and been approved for the treatment of neovascular fundus abnormalities[4].Existing pre-clinical and clinical research has shown the effectiveness of subconjunctival or corneal stromal injection of different anti-VEGF agents (e.g., bevacizumab,ranibizumab, and aflibercept) in the treatment of CNV[5-6].Conbercept (KH902; Chengdu Kanghong Biotech Co., China)is a recombinant fusion protein with key domains 2, 3, and 4 from VEGF receptors 1 and 2.Ⅰt has a high affinity for all VEGF isoforms as well as placental growth factors[7].In 2013,it was approved in China for the treatment of neovascular(wet) age-related macular degeneration and choroidal neovascularization secondary to pathological myopia[7].Whether conbercept could be used in the treatment of CNV is however largely unknown.The present study aimed thereforeto understand the effectiveness and safety of conberceptviasubconjunctival injection in modulating the characteristics of CNV.

    Table 1 Clinical characteristics of the 10 patients with corneal neovascularization

    SUBJECTS AND METHODS

    Ethical ApprovalThis study was additionally approved by the biomedical research ethics committee of Beijing Huimin Hospital (No.2018.1012).All recruited patients gave their written informed consent before their inclusion as participants in this study.

    Study ParticipantsThis is a case series study, including 10 patients with CNV who were consecutively recruited during December 2018-November 2019 in Beijing Huimin Hospital,Beijing, China.

    Ⅰnclusion criteria: age ≥18y, clinical diagnosis of CNV without active eye diseases, and neovascularization more than 2 mm into the corneal limbus.

    Exclusion criteria: corneal trauma, infection, or ophthalmic surgery during the past month; use of contact lenses during the past month; or severe systemic diseases.

    TreatmentLevofloxacin eye drops were applied four times a day for three days before the injection of conbercept.On the day of injection, we used proparacaine hydrochloride eye drops as anesthesia, iodophor solution to sterilize the skin around the eyes, and povidone-iodine solution to sterilize the conjunctival sac.We injected 0.1 mL of conbercept(10 mg/mL) into the corneoscleral limbus near the root of the new blood vessels.All injections were administered by the same ophthalmologist (Sun C).

    Study OutcomesVisual acuity and area, length, and diameter of neovascularization at five different time points (before treatment,1d, 1, 2wk, and 1mo after treatment), as well as systemic and ocular complications after treatment, were documented.Corneal images were taken at all five time points, using an anterior segment slit-lamp microscope at the magnification required to delineate the fine details of the vessels.

    Data AnalysisWe used Image pro plus 6.0 to measure the area, length, and diameter of neovascularization.Area was calculated by using the following formula: area(mm2)=CN/12×3.1416×[R2?(R?VL)2], where CN is the clock hours of neovascularization, R is the radius of the cornea, and VL is the longest vessel length, extending from the limbal vasculature[8].In terms of length, we identified three blood vessels with the greatest length in the densest quadrant of CNV and measured the greatest distance between the starting point of each vessel at the corneal limbus and anywhere along the vessel.We then calculated the mean value of the length of these three vessels as the measured length.In terms of diameter, we measured the diameters of all new blood vessels at the corneal limbus and calculated the average value as the diameter.

    Statistical AnalysisStatistical analysis was performed using SPSS 19.0.Shapiro-Wilk method was used to test the normality of data, and one-way repeated measure analysis of variance was used to compare data across the five time points.We also performed within-individual analysis to study the temporal trend of different parameters across the time points.Data are reported as mean±standard deviation (SD).AP<0.05 was considered statistically significant.

    RESULTS

    Clinical CharacteristicsAmong the 10 patients with CNV,all were male, with a mean age of 44±10.15y (Table 1).

    The mean±SD area of neovascularization was 42.46±12.80 mm2before treatment, and there was a statistically significant difference between all the time points after treatment and the time point before treatment (allP<0.05, Table 2, Figure 1).There was also a clearly declining area across the four different time points after treatment (F=31.373,P<0.001).

    The mean±SD length of neovascularization was 4.64±1.77 mm before treatment and there was a statistically significant difference between the length measured at 1, 2wk, as well as 1mo after treatment and the length measured before treatment(allP<0.01; Table 2, Figure 1).There was also a declining trend of length across the four time points after treatment(F=19.652,P<0.001).

    Figure 1 Outcomes of corneal neovascularization (CNV) parameters at five different time points A: CNV area; B: CNV length; C: CNV diameter.Compared with before treatment, aP<0.05, bP<0.01, cP<0.001.The significant therapeutic response which was evidenced as early as 1d, then peaked at 2wk, and reduced at 1mo.

    Figure 2 The effect of subconjunctival conbercept in patient 3, a 49-year-old man with chemical injury in the left eye complicated by corneal scarring, and neovascularization A: Baseline picture shows two main vessel branches emerging from the 12-o’clock and 5-o’clock position at the limbus and passing into the depressed scar in the corneal mid-periphery where it branched several times into smallercaliber vessels.B, C, D, E: 1d, 1, 2wk, and 1mo after subconjunctival conbercept.

    Table 2 Area, length, and diameter of neovascularization before and after subconjunctival conbercept

    The mean±SD diameter of neovascularization was 0.060±0.026 mm before treatment and there was a statistically significant difference between the diameter measured at 1wk,2wk, as well as 1mo after treatment and the diameter measured before treatment (allP<0.05; Table 2, Figure 1).There was also a declining trend of diameter across the four time points after treatment (F=16.661,P<0.001).

    The slit-lamp photographs of patient 3 were shown in Figure 2.

    DISCUSSION

    The formation of CNV is a complex process, involving vascular endothelial cells, keratinocytes, and inflammatory cells[9].Neovascular patterns can be separated into three groups, namely deep neovascularization overlying Descemet’s membrane (herpetic and luetic interstitial keratitis), stromal neovascularization (as a result of stromal keratitis), and vascular pannus (ocular surface disorders)[10].Multiple factors might contribute to the development of CNV.For instance,VEGF is the most important pro-angiogenic factor[2]and demonstrates a significantly increased concentration in the vascularized cornea[9].On the other hand, VEGF antagonists have been shown to reduce CNV in animal models[10], whereas anti-VEGF drugs have been shown to improve the survival rate of transplanted corneal grafts by restoring the “immune privilege”of the cornea[11].Subconjunctival bevacizumab,ranibizumab, and aflibercept crossed the blood and seemed to be effective in inhibiting CNV without causing epitheliopathy in an experimental rat model compared to the controls.No significant results were noted between these three anti-VEGF molecules, however, multiple-dose bevacizumab treatment seems to be more effective[11-12].

    Several anti-VEGF agents are currently used in clinical offlabel for the treatment of CNV, and most of them appear to be a safe, effective, and practical method[5,13-16].In the first report of human use of topical bevacizumab for CNV, two patients showed significant reductions in superficial and deep stromal neovascularization without impairment in the corneal endothelium[17].Others have also shown that perilimbal and intrastromal injection of bevacizumab before penetrating keratoplasty can improve surgical outcomes of high-risk patients[18].Ranibizumab, another monoclonal antibody against VEGF-A, has also been used to reduce CNV in both animal models and clinical studies[19-20].Aflibercept (VEGF TrapR1R2) has strong anti-VEGF activity and is a soluble fusion protein with binding domains for both VEGF receptors 1 and 2.Subconjunctival injection of aflibercept can reduce donor vascularization and improve graft survival in a high-risk graft murine model[21].However, Sellaet al[22]showed that a single subconjunctival aflibercept injection was ineffective to regress formed CNV.

    So far, the only topical antiangiogenic agent tested in phase II and III trials is aganirsen.Administration of topical aganirsen eye drops (86 μg/d per eye) in patients with keratitis related progressive CNV has been shown to lead to significant amelioration of CNV and reduced need for corneal transplantation[23].Although these agents are effective in the treatment of actively growing vessels, they have limited efficacy in well-established CNV[24].

    Conbercept can both bind to placental growth factor and all isoforms of VEGF-A and VEGF-B[25].As it has multiple targets, strong affinity, and a long half-life cycle, conbercept has proved to be effective and safe in the treatment of diabetic macular edema[26].In cases of refractory macular edema secondary to central retinal vein occlusion (CRVO), after switching from bevacizumab/ranibizumab, conbercept can improve macular thickness and extend interval of injection[27].Duet al[28]confirmed that conbercept, especially early administration, can effectively inhibit CNV in rabbits, intrastromal administrations has the better effect than subconjunctival injection.

    The present study used conbercept in patients with CNV and showed that the area of CNV reduced significantly already one day after treatment whereas the length and diameter of CNV reduced significantly one week after treatment.As the reduction in all three parameters peaked at two weeks after treatment, it might be beneficial to administer new injections to maintain or enhance effectiveness.For instance, although there were still significant reductions in all three indicators at one month after treatment, compared to the pre-treatment period,the magnitude of reductions diminished compared to two weeks after treatment.The observation time of this study was only 1mo, and it is speculated that with the extension of time(such as 3mo), the CNV may recur, suggesting the potential need of repeated treatments[15].Alternatively, for patients with stable CNV, transplantation of corneal graft might be considered at this time point, with the aim to achieve the best treatment effect for reducing neovascularization.

    Although all patients in the present study demonstrated a reduction in CNV after treatment, the reduction varied in magnitude and none of the patients had a complete resolution.There are multiple potential explanations for the partial effectiveness.First, the dosage administered in the present treatment is not sufficient to completely antagonize the corneal VEGF burden.Second, we only injected conbercept once and this might have led to a low cumulative concentration of the medication.Third, cytokines other than VEGF, such as transforming growth factor-α, transforming growth factor-β1,and fibroblast growth factor, can also induce CNV[29]and are not targeted by conbercept.Because neovascularization likely involves multiple processes, targeting VEGF alone might prevent the pro-angiogenic cascade but not others.Finally,conbercept works mostly on newly formed blood vessels,whereas our case series included patients with CNV due to different reasons and patients with both newly formed and long-standing neovascularization.As a result, some of the patients included in this study had more severe CNV with more mature vessels.As discussed above, the limited number of treatments might have also affected the treatment effectiveness.Previous evidence suggests that VEGF inhibitors can influence corneal healing by interfering with macrophage infiltration[30].Soleimaniet al[31]reported two cases with Descemet membrane detachment after intrastromal bevacizumab injection in patients with previous lamellar keratoplasty.The hemorrhagic Descemet membrane detachment was not resolved, the donor had to exchange with a new one because of staining in one of the patients.We should emphasize that the complications were not related to bevacizumab, instead the injection method was involved in these situations.In this study, we injected conbercept in the corneoscleral limbus near the root of the CNV to avoid damaging the corneal tissue.The subconjunctival injection may be a safer method, and the medication can however diffuse in a short distance through the conjunctival tissue to the central blood vessels.There was no thinning of the corneal epithelium or stroma, injury in corneal epithelium, conjunctivitis, keratitis, endophthalmitis,cataract, or other complications, demonstrating the safety of subconjunctival conbercept.

    In conclusion, subconjunctival conbercept may be an effective and safe option for the treatment of CNV, significantly reducing the area, length, and diameter of CNV without severe complications.Conbercept may also be considered an adjunct to other medical or surgical treatments of CNV.The use of conbercept for CNV is however still off-label.Further studies with a larger number of patients and longer followup are needed to validate our findings and to optimize the treatment regimen (e.g., number and timing of injections as well as injections versus other routes of administration).Comparison studies with other anti-VEGF agents are also helpful.

    ACKNOWLEDGEMENTS

    Foundation:Supported by the National Natural Science Foundation of China (No.81970764); the Youth Beijing Scholar (No.2020-022).

    Conflicts of Interest:Sun C, None; Ruan F, None; Li S,None; Zhang JQ, None; Jie Y, None.

    久久99精品国语久久久| 两个人看的免费小视频| 美女内射精品一级片tv| 国产无遮挡羞羞视频在线观看| 国产亚洲精品第一综合不卡 | 亚洲综合色惰| 99九九在线精品视频| 婷婷成人精品国产| 日韩在线高清观看一区二区三区| 国产高清不卡午夜福利| 精品一区二区免费观看| videossex国产| 在线亚洲精品国产二区图片欧美| av视频免费观看在线观看| 亚洲欧美精品自产自拍| 精品久久蜜臀av无| 亚洲精品日本国产第一区| 男女午夜视频在线观看 | 一本大道久久a久久精品| 三上悠亚av全集在线观看| 欧美激情国产日韩精品一区| 国产黄色免费在线视频| av一本久久久久| 久久久久网色| 日韩一区二区视频免费看| 国产精品久久久久久久电影| 国产麻豆69| 黄色怎么调成土黄色| 欧美成人午夜精品| 捣出白浆h1v1| 欧美精品一区二区免费开放| 中文字幕最新亚洲高清| 久热久热在线精品观看| 黄色一级大片看看| 欧美人与性动交α欧美精品济南到 | freevideosex欧美| 日本与韩国留学比较| 久久久精品94久久精品| 少妇熟女欧美另类| 高清视频免费观看一区二区| 欧美亚洲 丝袜 人妻 在线| 多毛熟女@视频| 国产精品嫩草影院av在线观看| 精品亚洲成a人片在线观看| 亚洲成色77777| 看非洲黑人一级黄片| 色视频在线一区二区三区| 国产黄色视频一区二区在线观看| 久久精品熟女亚洲av麻豆精品| 天堂中文最新版在线下载| 女人精品久久久久毛片| av女优亚洲男人天堂| 亚洲第一av免费看| 久久久久久久久久久久大奶| 日本猛色少妇xxxxx猛交久久| 亚洲四区av| 国产精品久久久av美女十八| 中文字幕另类日韩欧美亚洲嫩草| 国产成人免费观看mmmm| 色婷婷久久久亚洲欧美| 少妇被粗大的猛进出69影院 | 最近手机中文字幕大全| 91成人精品电影| 人体艺术视频欧美日本| 亚洲综合色网址| 99久国产av精品国产电影| 一个人免费看片子| a级毛片在线看网站| 九色成人免费人妻av| 精品一区二区三区视频在线| 巨乳人妻的诱惑在线观看| 狠狠婷婷综合久久久久久88av| 女人精品久久久久毛片| 久久精品夜色国产| 久久久久久久久久成人| 搡女人真爽免费视频火全软件| 国产1区2区3区精品| 三上悠亚av全集在线观看| 少妇高潮的动态图| 日本vs欧美在线观看视频| 咕卡用的链子| 成年动漫av网址| 母亲3免费完整高清在线观看 | 国精品久久久久久国模美| 女人被躁到高潮嗷嗷叫费观| 大香蕉久久网| 成人国语在线视频| 日韩 亚洲 欧美在线| 80岁老熟妇乱子伦牲交| 国产黄色免费在线视频| xxxhd国产人妻xxx| 亚洲少妇的诱惑av| av网站免费在线观看视频| 免费久久久久久久精品成人欧美视频 | 在线观看人妻少妇| 日韩一本色道免费dvd| 久久影院123| 婷婷成人精品国产| 免费观看av网站的网址| 午夜久久久在线观看| 国产精品99久久99久久久不卡 | 国产精品麻豆人妻色哟哟久久| 狠狠婷婷综合久久久久久88av| 国产成人精品婷婷| 另类精品久久| 久久久久久久久久人人人人人人| 国产成人91sexporn| 最近手机中文字幕大全| 日韩电影二区| 中文欧美无线码| 最近中文字幕高清免费大全6| 欧美成人精品欧美一级黄| 岛国毛片在线播放| 黑人高潮一二区| 亚洲国产色片| 精品少妇黑人巨大在线播放| 国产精品秋霞免费鲁丝片| 精品久久久精品久久久| 午夜视频国产福利| 少妇被粗大猛烈的视频| 亚洲av免费高清在线观看| 美女中出高潮动态图| a级毛片在线看网站| 亚洲情色 制服丝袜| 久久久久久久大尺度免费视频| 久久女婷五月综合色啪小说| 亚洲一级一片aⅴ在线观看| 亚洲欧美中文字幕日韩二区| 少妇被粗大的猛进出69影院 | 少妇 在线观看| 伦精品一区二区三区| 国产国语露脸激情在线看| 精品国产国语对白av| 又黄又爽又刺激的免费视频.| 亚洲精品aⅴ在线观看| 狂野欧美激情性xxxx在线观看| 妹子高潮喷水视频| 波野结衣二区三区在线| 欧美国产精品一级二级三级| 啦啦啦啦在线视频资源| 亚洲欧美精品自产自拍| 亚洲国产精品一区三区| 中文字幕亚洲精品专区| 午夜福利在线观看免费完整高清在| 高清av免费在线| a级毛色黄片| 国产欧美亚洲国产| 久久久国产一区二区| 久久久久国产精品人妻一区二区| 97超碰精品成人国产| 一区在线观看完整版| 咕卡用的链子| 久久久欧美国产精品| 国产一区二区在线观看日韩| 国产在视频线精品| 色5月婷婷丁香| 久久精品国产自在天天线| 久久精品国产综合久久久 | 在线观看美女被高潮喷水网站| 韩国精品一区二区三区 | 久久99热6这里只有精品| 亚洲精品美女久久av网站| 久久久久久伊人网av| 国产精品99久久99久久久不卡 | 亚洲精品一二三| 日韩伦理黄色片| 国语对白做爰xxxⅹ性视频网站| 精品一区二区三卡| 搡女人真爽免费视频火全软件| 各种免费的搞黄视频| 九色亚洲精品在线播放| 少妇被粗大的猛进出69影院 | a级毛色黄片| 90打野战视频偷拍视频| 欧美精品av麻豆av| videos熟女内射| 一级片免费观看大全| 综合色丁香网| 一个人免费看片子| 看非洲黑人一级黄片| 国内精品宾馆在线| 看免费成人av毛片| 多毛熟女@视频| 在线亚洲精品国产二区图片欧美| 天堂中文最新版在线下载| 久久影院123| 国产日韩欧美视频二区| 香蕉丝袜av| 男女高潮啪啪啪动态图| 丝瓜视频免费看黄片| 最近最新中文字幕大全免费视频 | 全区人妻精品视频| 91在线精品国自产拍蜜月| 一级爰片在线观看| 看非洲黑人一级黄片| 在线 av 中文字幕| 久久久久久久久久久免费av| 久久人人爽人人爽人人片va| 亚洲成人一二三区av| 国产av码专区亚洲av| 黑人猛操日本美女一级片| 天天躁夜夜躁狠狠躁躁| 在线看a的网站| 国产精品女同一区二区软件| 国产高清三级在线| 欧美日韩精品成人综合77777| 一本大道久久a久久精品| 亚洲国产精品999| www.色视频.com| 少妇熟女欧美另类| 满18在线观看网站| 精品少妇内射三级| 亚洲成av片中文字幕在线观看 | 男人舔女人的私密视频| 大片电影免费在线观看免费| 我要看黄色一级片免费的| 精品亚洲乱码少妇综合久久| 美女脱内裤让男人舔精品视频| 国产精品秋霞免费鲁丝片| 九九在线视频观看精品| 精品亚洲成a人片在线观看| 中文字幕人妻熟女乱码| 丝袜人妻中文字幕| 两性夫妻黄色片 | 少妇精品久久久久久久| 亚洲精品美女久久av网站| 亚洲一码二码三码区别大吗| 国产精品人妻久久久影院| 亚洲高清免费不卡视频| 内地一区二区视频在线| 亚洲经典国产精华液单| 天天躁夜夜躁狠狠久久av| 免费不卡的大黄色大毛片视频在线观看| 国国产精品蜜臀av免费| 久久久精品94久久精品| 精品久久久精品久久久| 免费黄色在线免费观看| 韩国精品一区二区三区 | 婷婷色麻豆天堂久久| 亚洲天堂av无毛| 一级毛片 在线播放| 黑人猛操日本美女一级片| 国产av国产精品国产| 亚洲四区av| 最近2019中文字幕mv第一页| 国产日韩欧美视频二区| 99热6这里只有精品| 精品少妇久久久久久888优播| 亚洲国产av影院在线观看| 午夜久久久在线观看| 王馨瑶露胸无遮挡在线观看| 国产精品久久久久久精品古装| 亚洲精品久久成人aⅴ小说| 寂寞人妻少妇视频99o| 草草在线视频免费看| 亚洲精品国产色婷婷电影| 少妇猛男粗大的猛烈进出视频| 性色av一级| 久久狼人影院| 久久人妻熟女aⅴ| 亚洲精品,欧美精品| 欧美人与性动交α欧美精品济南到 | 国产综合精华液| 日韩一区二区三区影片| 捣出白浆h1v1| 一区二区av电影网| 日韩欧美精品免费久久| 欧美成人精品欧美一级黄| 亚洲欧美成人精品一区二区| 午夜福利在线观看免费完整高清在| 波多野结衣一区麻豆| 国产亚洲最大av| 国产黄色视频一区二区在线观看| 激情视频va一区二区三区| 韩国精品一区二区三区 | 中文字幕人妻熟女乱码| 久久人人爽人人爽人人片va| 看免费av毛片| 在线免费观看不下载黄p国产| 巨乳人妻的诱惑在线观看| 99视频精品全部免费 在线| 色吧在线观看| 国产一区亚洲一区在线观看| 欧美日韩av久久| 中文字幕免费在线视频6| 欧美激情国产日韩精品一区| 街头女战士在线观看网站| 亚洲av福利一区| 日韩欧美精品免费久久| 亚洲成人一二三区av| 久久亚洲国产成人精品v| 日韩人妻精品一区2区三区| 中文精品一卡2卡3卡4更新| 嫩草影院入口| 一级毛片我不卡| 最近的中文字幕免费完整| 精品99又大又爽又粗少妇毛片| h视频一区二区三区| 久久精品国产亚洲av涩爱| 男女啪啪激烈高潮av片| 精品一区二区三区四区五区乱码 | 亚洲在久久综合| 中文字幕人妻丝袜制服| 色吧在线观看| 久久久久久久精品精品| 久久久久网色| 国产在线一区二区三区精| 女人久久www免费人成看片| 视频区图区小说| 91精品伊人久久大香线蕉| 亚洲精品日本国产第一区| 九九爱精品视频在线观看| 免费在线观看完整版高清| 免费女性裸体啪啪无遮挡网站| 欧美bdsm另类| 男女高潮啪啪啪动态图| 精品久久久精品久久久| 欧美 日韩 精品 国产| 热99久久久久精品小说推荐| 最新的欧美精品一区二区| 少妇的丰满在线观看| 美女福利国产在线| 国产精品国产三级国产专区5o| 国产高清三级在线| 亚洲国产日韩一区二区| 日韩一本色道免费dvd| 男女边吃奶边做爰视频| 9191精品国产免费久久| 女人被躁到高潮嗷嗷叫费观| 国产精品国产av在线观看| 狠狠婷婷综合久久久久久88av| 日本av免费视频播放| 午夜激情久久久久久久| 久久精品久久久久久久性| 亚洲三级黄色毛片| 久久女婷五月综合色啪小说| 黄片无遮挡物在线观看| 日本猛色少妇xxxxx猛交久久| 久久精品久久精品一区二区三区| 午夜激情av网站| 成人午夜精彩视频在线观看| 国产熟女欧美一区二区| av免费观看日本| 狂野欧美激情性xxxx在线观看| 99久国产av精品国产电影| 丝瓜视频免费看黄片| 亚洲成av片中文字幕在线观看 | 亚洲国产看品久久| 一级毛片黄色毛片免费观看视频| 少妇人妻 视频| 色视频在线一区二区三区| 久久久久国产精品人妻一区二区| 18+在线观看网站| 久久99一区二区三区| 一本色道久久久久久精品综合| 91精品国产国语对白视频| 亚洲av综合色区一区| 亚洲人成网站在线观看播放| 亚洲av日韩在线播放| 在线观看国产h片| 侵犯人妻中文字幕一二三四区| 精品一品国产午夜福利视频| 肉色欧美久久久久久久蜜桃| 亚洲av成人精品一二三区| 久久精品久久精品一区二区三区| 国产日韩欧美视频二区| 色5月婷婷丁香| 丝袜人妻中文字幕| 国产高清国产精品国产三级| 人妻少妇偷人精品九色| 久久久久久久亚洲中文字幕| 中文字幕人妻丝袜制服| 十分钟在线观看高清视频www| 丝袜美足系列| 久久久a久久爽久久v久久| 成人亚洲欧美一区二区av| 成人国产麻豆网| 男男h啪啪无遮挡| 国产欧美日韩一区二区三区在线| 99国产精品免费福利视频| 蜜臀久久99精品久久宅男| 最近中文字幕高清免费大全6| 青春草国产在线视频| 久久av网站| 亚洲美女黄色视频免费看| 黄色怎么调成土黄色| 欧美3d第一页| 免费看光身美女| 人人妻人人澡人人看| 精品少妇内射三级| 自线自在国产av| 亚洲成人av在线免费| 国产成人91sexporn| 人妻人人澡人人爽人人| 91成人精品电影| 制服丝袜香蕉在线| 日本av手机在线免费观看| 妹子高潮喷水视频| 欧美激情国产日韩精品一区| 制服诱惑二区| 看免费av毛片| 国产在线一区二区三区精| 中文字幕另类日韩欧美亚洲嫩草| 99久久中文字幕三级久久日本| 人成视频在线观看免费观看| 国产成人精品婷婷| 丝袜脚勾引网站| a级片在线免费高清观看视频| 亚洲精品,欧美精品| 黄色毛片三级朝国网站| 国产日韩欧美亚洲二区| 永久免费av网站大全| 日韩成人av中文字幕在线观看| 香蕉精品网在线| 黑丝袜美女国产一区| 在线观看三级黄色| 亚洲精品第二区| 久久久久国产网址| 国产成人免费观看mmmm| av女优亚洲男人天堂| 免费大片黄手机在线观看| 久久这里只有精品19| 久久国内精品自在自线图片| 午夜视频国产福利| 亚洲熟女精品中文字幕| 美女福利国产在线| 国产成人精品一,二区| 国产精品 国内视频| 观看美女的网站| 十八禁高潮呻吟视频| 亚洲国产精品一区二区三区在线| 中文字幕最新亚洲高清| 欧美成人午夜免费资源| 国产免费福利视频在线观看| 中文字幕最新亚洲高清| 国产爽快片一区二区三区| 狠狠婷婷综合久久久久久88av| 国产成人a∨麻豆精品| a级片在线免费高清观看视频| 国产欧美另类精品又又久久亚洲欧美| 狂野欧美激情性bbbbbb| av在线app专区| 久久99精品国语久久久| 久久人人爽人人片av| 欧美日韩成人在线一区二区| 水蜜桃什么品种好| 丰满饥渴人妻一区二区三| 亚洲精华国产精华液的使用体验| 欧美国产精品一级二级三级| 欧美97在线视频| 亚洲一级一片aⅴ在线观看| 高清毛片免费看| 免费观看a级毛片全部| 亚洲精品成人av观看孕妇| 中文字幕另类日韩欧美亚洲嫩草| 日本免费在线观看一区| 久久午夜综合久久蜜桃| 国产乱人偷精品视频| 婷婷色麻豆天堂久久| 一二三四中文在线观看免费高清| 国产一区有黄有色的免费视频| 伊人亚洲综合成人网| 啦啦啦视频在线资源免费观看| 宅男免费午夜| 国产精品人妻久久久影院| 亚洲国产成人一精品久久久| 22中文网久久字幕| 男男h啪啪无遮挡| 在线观看免费视频网站a站| 久久精品国产自在天天线| 午夜激情av网站| 成人免费观看视频高清| 搡老乐熟女国产| 新久久久久国产一级毛片| 久久99蜜桃精品久久| 中文字幕精品免费在线观看视频 | 五月伊人婷婷丁香| 夜夜骑夜夜射夜夜干| 国产毛片在线视频| 亚洲av.av天堂| 国产精品一区www在线观看| 九九在线视频观看精品| 中国国产av一级| 在线观看人妻少妇| av播播在线观看一区| 我要看黄色一级片免费的| 久久av网站| xxx大片免费视频| 欧美成人精品欧美一级黄| 国产免费一级a男人的天堂| 久久97久久精品| 国产淫语在线视频| 日本wwww免费看| 一边摸一边做爽爽视频免费| 久久国产精品大桥未久av| 亚洲 欧美一区二区三区| 秋霞伦理黄片| 一级片'在线观看视频| 精品亚洲成国产av| 亚洲国产精品专区欧美| 久久精品国产亚洲av天美| 国产国语露脸激情在线看| 国产精品蜜桃在线观看| 免费观看a级毛片全部| 少妇熟女欧美另类| av网站免费在线观看视频| 欧美国产精品va在线观看不卡| 国产男女超爽视频在线观看| 少妇猛男粗大的猛烈进出视频| 深夜精品福利| 亚洲情色 制服丝袜| 人妻一区二区av| 欧美性感艳星| 国产av一区二区精品久久| 丰满乱子伦码专区| 一区二区日韩欧美中文字幕 | 亚洲 欧美一区二区三区| 国产黄色视频一区二区在线观看| 成人毛片60女人毛片免费| 国产精品一区www在线观看| 蜜臀久久99精品久久宅男| 啦啦啦啦在线视频资源| 黄片无遮挡物在线观看| 飞空精品影院首页| 国产极品粉嫩免费观看在线| 欧美精品亚洲一区二区| 国产精品久久久久久久电影| 国语对白做爰xxxⅹ性视频网站| 亚洲在久久综合| 亚洲欧洲日产国产| 人妻 亚洲 视频| 青青草视频在线视频观看| 成人亚洲精品一区在线观看| 亚洲四区av| 视频在线观看一区二区三区| 亚洲av综合色区一区| 久久这里只有精品19| 国产xxxxx性猛交| 在线观看三级黄色| 赤兔流量卡办理| 在线观看国产h片| 国产在线视频一区二区| 日韩欧美精品免费久久| 最近最新中文字幕大全免费视频 | 超碰97精品在线观看| 少妇的逼水好多| 极品少妇高潮喷水抽搐| 人人妻人人澡人人看| 黄色 视频免费看| 国产精品无大码| 亚洲精品第二区| 一区二区三区精品91| 热re99久久精品国产66热6| 日产精品乱码卡一卡2卡三| 国产精品一二三区在线看| 91aial.com中文字幕在线观看| 中文字幕制服av| 亚洲伊人久久精品综合| 91成人精品电影| 啦啦啦在线观看免费高清www| 亚洲精品久久成人aⅴ小说| 亚洲国产欧美在线一区| 国产免费又黄又爽又色| 国产一区亚洲一区在线观看| av在线老鸭窝| 亚洲国产欧美在线一区| 久久国产精品男人的天堂亚洲 | 欧美精品亚洲一区二区| 男女啪啪激烈高潮av片| 午夜激情av网站| freevideosex欧美| 少妇 在线观看| 两性夫妻黄色片 | 精品人妻熟女毛片av久久网站| 久久国产亚洲av麻豆专区| 中文字幕另类日韩欧美亚洲嫩草| 丝袜脚勾引网站| 久久99蜜桃精品久久| 欧美 日韩 精品 国产| 欧美人与性动交α欧美精品济南到 | 交换朋友夫妻互换小说| 欧美成人午夜精品| 久久精品国产自在天天线| 国产亚洲av片在线观看秒播厂| 国产精品三级大全| 亚洲,欧美,日韩| 国产免费一区二区三区四区乱码| 人人妻人人澡人人爽人人夜夜| 日韩欧美精品免费久久| 国产熟女欧美一区二区| 成年人午夜在线观看视频| 亚洲av欧美aⅴ国产| 亚洲欧美中文字幕日韩二区| 男女边摸边吃奶| 欧美成人午夜精品| freevideosex欧美| 水蜜桃什么品种好| 亚洲精品日韩在线中文字幕| 亚洲精品456在线播放app| 五月伊人婷婷丁香| videos熟女内射| 国产亚洲午夜精品一区二区久久| 欧美变态另类bdsm刘玥| 美女xxoo啪啪120秒动态图| 国产探花极品一区二区| 中文字幕av电影在线播放| 免费高清在线观看日韩| 99久国产av精品国产电影| 欧美精品一区二区大全| 天堂俺去俺来也www色官网| 99热国产这里只有精品6| 乱码一卡2卡4卡精品| 久久久国产一区二区| 欧美激情 高清一区二区三区| av在线播放精品|